InMed Pharmaceuticals

What causes age-related #macular #degeneration #AMD? How does it develop? One of the hallmarks of dry AMD is the accumulation of yellowish deposits known as drusen. Drusen is secreted by the retinal epithelium pigment (RPE) cells and can damage the integrity of the macula or back of the eye responsible for central vision. More on AMD including resources: https://ow.ly/4KN550UChaO $INM #eyedisease #eyehealth #dryAMD

InMed has initiated three pharmaceutical programs targeting #CB1 and #CB2 pathways. This includes preclinical programs in #Alzheimers disease and age-related macular degeneration #AMD, as well as a completed Phase 2 clinical trial for #epidermolysis #bullosa. More on our pipeline: https://ow.ly/X4LR50UAG7u $INM

How do #genetics play a factor in the development and progression of #Alzheimer's disease? According to a report by the Alzheimer's Association®, researchers identified 31 new genes that appear to affect the biological processes that increase or decrease the risk of #Alzheimers. 2024 Alzheimer's Facts and Figures: https://ow.ly/lfAH50UAFWK $INM

In this webinar, #Alzheimers experts talk about the future of treating this disease. "We're not going to treat this disease with one drug. And we don't even treat hypertension with one drug. So there's room for a lot of different novel approaches that will ultimately, I think, be synergistic in helping to arrest progression of the disease." ~Dr. David Morgan, Michigan State University Webinar replay: https://ow.ly/pvOX50Uz0zk $INM

Happy New Year! From our team at InMed, we wish you a year of success, innovation and resilience!

#Alzheimer's experts say this is a time of major advancements in #Alzheimers research that will improve outcomes for patients. "We're on the precipice of massive new knowledge about this disease that's going to happen over the next few years, and we can't even imagine what that new knowledge is going to do for us" ~Dr. Barry Greenberg, Johns Hopkins School of Medicine Experts come together in this informative webinar: https://ow.ly/XV3j50UuzmY $INM

There are 39 drugs being repurposed for the potential treatment of #Alzheimers disease. A study of a GLP-1 agonist, part of a class of drugs used for diabetes, weight loss and heart disease, demonstrated neuroprotective effects that may help to protect the brain. Such studies show the potential of exploring drug candidates that target pathways linked to neuroprotection or anti-inflammation. 2024 Alzheimer's pipeline: https://ow.ly/acqW50Uvbzc $INM

In last decade, there have been major breakthroughs in #Alzheimer's research - changing the course of the disease and how it's treated. Article "The Evolving Alzheimer’s Disease Landscape" goes over the new therapies, what researchers are learning about pathological factors and the emerging blood-based biomarker tests. https://ow.ly/SpcX50UvaBa $INM

From all of us at InMed, wishing you and yours peace and joy this holiday season.

#Alzheimer's experts share their thoughts on changing the course of the disease and what's on the horizon for therapeutic development. "Even though we now have two major breakthrough drugs, we're still early in the therapeutic days. We're in the beginning of transforming #Alzheimers from a terminal disease, as you and I know it, to a chronic disease. This is the diabetes and HIV of our time." ~Dr. Marwan Sabbagh, Barrow Neurological Institute Watch the replay of this Fierce Biotech webinar: https://ow.ly/RaJg50Uux0s $INM